Story perspectives

FDA Labels Vitruvias 30mg Thyroid Recall Class I

By Drooid · Sep 25, 2026, 12:21 AM UTC · How we work

Summary

Story summary

The U.S. Food and Drug Administration classified Vitruvias Therapeutics’ 30 mg thyroid tablet recall as Class I on Sept. 22, 2026.
Vitruvias recalled one lot because the tablets could be superpotent.
About 1,900 units were sold from a batch of roughly 3,600.
The tablets were distributed nationwide from Jan. 31 to Sept. 30, 2025 and expire Sept. 30, 2026.
Vitruvias reported no adverse events as of Aug. 24, 2026 and advises consumers not to stop use without a health-care provider.

1 of 1

Story summary

The U.S. Food and Drug Administration classified Vitruvias Therapeutics’ 30 mg thyroid tablet recall as Class I on Sept. 22, 2026.
Vitruvias recalled one lot because the tablets could be superpotent.
About 1,900 units were sold from a batch of roughly 3,600.
The tablets were distributed nationwide from Jan. 31 to Sept. 30, 2025 and expire Sept. 30, 2026.
Vitruvias reported no adverse events as of Aug. 24, 2026 and advises consumers not to stop use without a health-care provider.